Systemic adjuvant treatment of high-risk melanoma: the role of interferon Alfa-2b and other immunotherapies

This publication has 15 references indexed in Scilit:

• Future perspectives in specific immunotherapy of melanoma
  European Journal Of Cancer, 1998
• Long term results of an adjuvant therapy with low doses IFN-??2A in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases
  Melanoma Research, 1997
• Development of Cancer Immunotherapies Based on Identification of the Genes Encoding Cancer Regression Antigens
  JNCI Journal of the National Cancer Institute, 1996
• The prognostic significance of immune changes in patients with renal cancer, melanoma and colorectal cancer, treated with interferon α2b
  Cancer Immunology, Immunotherapy, 1996
• New treatment options for patients with melanoma: review of melanoma-derived T-cell epitope-based peptide vaccines
  Melanoma Research, 1996
• Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma.
  Journal of Clinical Oncology, 1995
• Model Predicting Survival in Stage I Melanoma Based on Tumor Progression
  JNCI Journal of the National Cancer Institute, 1989
• A Comparison of Prognostic Factors and Surgical Results in 1,786 Patients with Localized (Stage I) Melanoma Treated in Alabama, USA, and New South Wales, Australia
  Annals of Surgery, 1982
• A Multifactorial Analysis of Melanoma
  Annals of Surgery, 1981
• A Multifactorial Analysis of Melanoma
  Annals of Surgery, 1978